Urinary PGE-M: a Promising Cancer Biomarker

Overview

Journal Cancer Prev Res (Phila)

Specialty Oncology

Date 2013 May 3

PMID 23636051

Citations 35

Authors

Dingzhi Wang

Raymond N DuBois

Affiliations

Soon will be listed here.

Abstract

Cancer prevention, early diagnosis, and targeted therapies are the keys to success in better cancer control and treatment. A big challenge remains to identify biomarkers for predicting who may have higher cancer risk and are able to respond to certain chemopreventive agents as well as for assessing a patient's response during treatment. Although a large body of evidence indicates that chronic inflammation is a risk factor for cancer, it is unclear whether inflammatory biomarkers can be used to predict cancer risk, progression, and death. Considering the importance of the proinflammatory COX-2-derived prostaglandin E2 (PGE2) in inflammation and cancer, Morris and colleagues found that urinary PGE-M is positively associated with obesity, smoking, and lung metastases in patients with breast cancer (4). Along the same lines, Kim and colleagues showed a potential association between urinary PGE-M and breast cancer risk in postmenopausal women (beginning on page 511). In agreement with previous reports, their findings indicate that urinary PGE-M may serve as a promising biomarker for prognosticating cancer risk and disease progression.

Citing Articles

Optimizing aspirin dose for colorectal cancer patients through deep phenotyping using novel biomarkers of drug action.

Patrignani P, Tacconelli S, Contursi A, Piazuelo E, Bruno A, Nobili S Front Pharmacol. 2024; 15:1362217.

PMID: 38495101 PMC: 10941341. DOI: 10.3389/fphar.2024.1362217.

Predictors of upstream inflammation and oxidative stress pathways during early pregnancy.

Welch B, Bommarito P, Cantonwine D, Milne G, Motsinger-Reif A, Edin M Free Radic Biol Med. 2024; 213:222-232.

PMID: 38262546 PMC: 10922808. DOI: 10.1016/j.freeradbiomed.2024.01.022.

Biomarkers of Response to Low-Dose Aspirin in Familial Adenomatous Polyposis Patients.

Lanas A, Tacconelli S, Contursi A, Piazuelo E, Bruno A, Ronci M Cancers (Basel). 2023; 15(9).

PMID: 37173923 PMC: 10177499. DOI: 10.3390/cancers15092457.

Correlation between Metabolite of Prostaglandin E2 and the incidence of colorectal adenomas.

Jiang J, Li A, Lai X, Zhang H, Wang C, Wang H Front Oncol. 2023; 13:1068469.

PMID: 36923425 PMC: 10009184. DOI: 10.3389/fonc.2023.1068469.

Prognostic implications of prostaglandin E-major urinary metabolite in resected non-small-cell lung cancer.

Mikubo M, Satoh Y, Ono M, Sonoda D, Hayashi S, Naito M Interdiscip Cardiovasc Thorac Surg. 2023; 36(1).

PMID: 36802257 PMC: 9931073. DOI: 10.1093/icvts/ivac291.

References

Hambek M, Baghi M, Wagenblast J, Schmitt J, Baumann H, Knecht R . Inverse correlation between serum PGE2 and T classification in head and neck cancer. Head Neck. 2006; 29(3):244-8. DOI: 10.1002/hed.20503. View

Eberhart C, Coffey R, Radhika A, Giardiello F, Ferrenbach S, DuBois R . Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994; 107(4):1183-8. DOI: 10.1016/0016-5085(94)90246-1. View

Rothwell P, Price J, Fowkes F, Zanchetti A, Roncaglioni M, Tognoni G . Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012; 379(9826):1602-12. DOI: 10.1016/S0140-6736(11)61720-0. View

Chan A, Ogino S, Fuchs C . Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007; 356(21):2131-42. DOI: 10.1056/NEJMoa067208. View

Morris P, Zhou X, Milne G, Goldstein D, Hawks L, Dang C . Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer. Cancer Prev Res (Phila). 2013; 6(5):428-36. PMC: 3752669. DOI: 10.1158/1940-6207.CAPR-12-0431. View

Kim S, Taylor J, Milne G, Sandler D . Association between urinary prostaglandin E2 metabolite and breast cancer risk: a prospective, case-cohort study of postmenopausal women. Cancer Prev Res (Phila). 2013; 6(6):511-8. PMC: 3677792. DOI: 10.1158/1940-6207.CAPR-13-0040. View

Duffield-Lillico A, Boyle J, Zhou X, Ghosh A, Butala G, Subbaramaiah K . Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila). 2009; 2(4):322-9. PMC: 2745265. DOI: 10.1158/1940-6207.CAPR-09-0005. View

Rigas B, Goldman I, Levine L . Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993; 122(5):518-23. View

Sinicrope F, Foster N, Sargent D, OConnell M, Rankin C . Obesity is an independent prognostic variable in colon cancer survivors. Clin Cancer Res. 2010; 16(6):1884-93. PMC: 2948494. DOI: 10.1158/1078-0432.CCR-09-2636. View

10.

Seyberth H, Sweetman B, Frolich J, OATES J . Quantifications of the major urinary metabolite of the E prostaglandins by mass spectrometry: evaluation of the method's application to clinical studies. Prostaglandins. 1976; 11(2):381-97. DOI: 10.1016/0090-6980(76)90160-x. View

11.

Mutter R, Lu B, Carbone D, Csiki I, Moretti L, Johnson D . A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin Cancer Res. 2009; 15(6):2158-65. DOI: 10.1158/1078-0432.CCR-08-0629. View

12.

Xia D, Wang D, Kim S, Katoh H, DuBois R . Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med. 2012; 18(2):224-6. PMC: 3274627. DOI: 10.1038/nm.2608. View

13.

Ogino S, Kirkner G, Nosho K, Irahara N, Kure S, Shima K . Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res. 2008; 14(24):8221-7. PMC: 2679582. DOI: 10.1158/1078-0432.CCR-08-1841. View

14.

Johnson J, Schmidt C, Shrubsole M, Billheimer D, Joshi P, Morrow J . Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol. 2006; 4(11):1358-65. DOI: 10.1016/j.cgh.2006.07.015. View

15.

Harris R . Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009; 17(2):55-67. DOI: 10.1007/s10787-009-8049-8. View

16.

Ferretti A, Flanagan V, Roman J . Quantitative analysis of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostanoic acid, the major urinary metabolite of E prostaglandins in man. Anal Biochem. 1983; 128(2):351-8. DOI: 10.1016/0003-2697(83)90385-8. View

17.

Algra A, Rothwell P . Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13(5):518-27. DOI: 10.1016/S1470-2045(12)70112-2. View

18.

Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A . Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002; 33(7):708-14. DOI: 10.1053/hupa.2002.125376. View

19.

Murphey L, Williams M, Sanchez S, Byrne L, Csiki I, Oates J . Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Anal Biochem. 2004; 334(2):266-75. DOI: 10.1016/j.ab.2004.08.019. View

20.

DuBois R, Abramson S, Crofford L, Gupta R, Simon L, van de Putte L . Cyclooxygenase in biology and disease. FASEB J. 1998; 12(12):1063-73. View